Oral edaravone demonstrated a favorable safety profile in patients with amyotrophic lateral sclerosis after 48 weeks of treatment

INTRODUCTION/AIMS: An intravenous (IV) formulation of edaravone has been shown to slow the rate of physical functional decline in amyotrophic lateral sclerosis (ALS). An oral suspension formulation of edaravone was recently approved by the United States Food and Drug Administration for use in patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Genge, Angela, Pattee, Gary L., Sobue, Gen, Aoki, Masashi, Yoshino, Hiide, Couratier, Philippe, Lunetta, Christian, Petri, Susanne, Selness, Daniel, Bidani, Sachin, Hirai, Manabu, Sakata, Takeshi, Salah, Alejandro, Apple, Stephen, Wamil, Art, Kalin, Alexander, Jackson, Carlayne E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2022
Materias:
Clinical Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10107134/
https://www.ncbi.nlm.nih.gov/pubmed/36504406
http://dx.doi.org/10.1002/mus.27768

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10107134/
https://www.ncbi.nlm.nih.gov/pubmed/36504406
http://dx.doi.org/10.1002/mus.27768

Ejemplares similares